Comparing R-CMOP and R-CHOP for first-time DLBCL treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests if a new drug combination (R-CMOP) works as well as or better than the usual combination (R-CHOP) for people with a type of lymphoma called DLBCL who haven't had treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with DLBCL (a common type of lymphoma).
- You have not received any previous treatment for DLBCL.
- You have at least one tumor that can be measured on a scan.
- You are in generally good health (able to do daily activities).
- Your doctor expects you to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (R-CMOP) for people who have just been diagnosed with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) and have not yet received any treatment for it. The goal is to see if this treatment works well and is safe.
This trial compares two different shortened treatment schedules of R-CHOP to see which one is safer and works better for people with low-risk diffuse large B-cell lymphoma (DLBCL). It aims to reduce risk from treatment while maintaining strong cancer control after an initial response.
This trial tests a new combination treatment (DZD8586) for people with diffuse large B-cell lymphoma (DLBCL). It looks at how well the drug works and how safe it is for both newly diagnosed patients and those whose cancer returned after initial treatment.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.